X

Acute Myeloid Leukemia

Acute Myeloid Leukemia

Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed.

Journal of Hematology & Oncology
05/13/2022

IDH1 mutation limits the flexibility for citrate utilization in the presence of impaired complex I activity to a degree that is not apparent in IDH2 mutant cells, exposing a mutation-specific...

Nature Communications
05/12/2022

Here, we first tested a novel oxime-containing derivative of 2-((2,4,5-trifluorobenzyl)oxy)benzaldehyde oxime (TFOBO) to evaluate its anticancer effect in myeloid leukemic cells.

Scientific Reports
05/07/2022

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer...

Medical Xpress
05/09/2022

We performed a retrospective analysis of 87 newly diagnosed FLT3 mutated AML patients treated on triplet (LIC + FLT3 inhibitor + Venetoclax, [N = 27]) and doublet...

Blood Cancer Journal
05/02/2022

Montesinos et al found that the addition of ivosidenib to azacitidine in induction therapy significantly prolonged event-free survival in patients with newly diagnosed IDH1-mutated AML.

The ASCO Post
05/02/2022

Massachusetts General Hospital (MGH) researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy...

Medical Xpress
04/28/2022

In this study, we reported that Triptolide synergized with MDM2 inhibitor Nutlin-3a to suppress cell proliferation and induce mitochondrial-mediated apoptosis...

Experimental Hematology & Oncology
04/16/2022

We used cross-sectional secondary data analyses to describe coping in 160 patients with newly diagnosed high-risk AML. 

Blood Advances
04/11/2022

Our study aims to explore the cell differentiation effect of a potent histone deacetylase inhibitor (HDACi), I13, and its possible mechanism on AML cell lines.

Frontiers in Oncology
04/12/2022

Pollard et al found that the addition of sorafenib to standard chemotherapy may benefit pediatric patients with high allelic ratio FLT3-ITD–positive acute myeloid leukemia (AML).

The ASCO Post
04/05/2022

The purpose of this research is to identify the key lncRNAs and explore their functions in CN-AML by reconstructing the lncRNA–miRNA–mRNA network based on the...

Scientific Reports
03/23/2022

IDH2 expression in AML cell lines and patient samples was evaluated by RT-qPCR, western blotting and database analyses. 

Journal of Hematology & Oncology
03/21/2022

In this study, we hypothesized that presence of IDH1 c.315C>T SNP does not impact clinical outcome of AML patients because of the lack of amino acid (glycine, Gly) change in position 10

Frontiers in Oncology
03/18/2022

The findings suggest that these patients may benefit from additional novel therapies in the conditioning regimen or post-transplant stage.

Hematology Advisor
03/03/2022

In order to better treat patients diagnosed with acute myeloid leukemia (AML), the pathological processes and also existing subtypes of the disease must be better understood.

Medical Xpress
03/04/2022

A new mutation was identified in 9% of relapsed cases of pediatric acute myeloid leukemia (AML) that may define a new subtype of the disease...

The ASCO Post
02/24/2022

Scientists evaluated the potential for emvododstat to inhibit the progression of acute myeloid leukemia using several in vitro and in vivo models of the disease. 

Frontiers in Oncology
02/09/2022

Gilteritinib may improve long-term outcomes, compared with salvage chemotherapy, in patients with R/R FLT3-mutated AML, according to updated data from the ADMIRAL trial published in Blood.

Hematology Advisor
02/07/2022

In AML patients who were ineligible for intensive chemotherapy, the addition of the IDH1 inhibitor ivosidenib to azacitidine significantly improved survival vs azacitidine alone. 

The ASCO Post
01/14/2022

Black AYAs with AML have shorter OS than White AYAs with AML, according to research presented at the 2021 ASH Annual Meeting.

Cancer Therapy Advisor
12/21/2021

Dexamethasone exhibits antileukemic properties in patients who have acute myeloid leukemia and prolongs survival, according to a new study.

Oncology Times - Latest Articles
12/20/2021

Researchers recently identified the RUNX3 gene as an oncogene in AML cells in a new study with results reported in Frontiers in Oncology.

Hematology Advisor
12/21/2021

Researchers use trial-level and patient-level data from trials of intensive chemotherapy in patients with newly diagnosed AML to examine the relationship between CR rate and EFS with OS.

Journal of Clinical Oncology
12/10/2021

An analysis of the ASH RC COVID-19 Registry of patients with AML, MDS, or ALL found that active disease was associated with an increased risk of developing severe COVID-19. 

Cancer Therapy Advisor
12/11/2021

An analysis of the phase 3 ASTRAL-2 trial did not show an OS benefit with guadecitabine in patients with R/R AML, but possible benefits were seen for some subgroups. 

Hematology Advisor
12/13/2021

This study reports diverging trends in the risk of tAML and tMDS after adoption of modern cancer therapies for specific cancers.

Scientific Reports
12/02/2021

Scientists investigated the expression, prognostic significance, and functional role of the Receptor Activator of Nuclear Factor-κB in AML.

Cancers
12/04/2021

This research suggests that prophylactic MCF is safe and effective in pts with newly diagnosed AML undergoing induction chemotherapy.

Open Forum Infectious Diseases
12/04/2021

Researchers conducted a classic dropout viability screen in combination with a minimal dose of either azacytidine or cytarabine to uncover targets whose depletion decreases viability...

Scientific Reports
12/02/2021

Scientists investigate the impact of perioperative neutropenia on development of CESI and CLABSI in a large and well-defined cohort of highly vulnerable pediatric AML patients...

Frontiers in Oncology
11/23/2021

This research suggests that the sEV-related miR-19a-3p may represent a potential therapeutic target for NPM1mut AML.

Journal of Extracellular Vesicles
11/22/2021

Researchers found that BETi, similar to ATO + ATRA, induced differentiation and apoptosis which was TP53 independent in the NPM1c cell line OCI-AML3 and primary cells. 

Biomedicines
11/17/2021

source list reference

RGB(78, 191, 50)
rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(80,199,199)
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(80,199,199)
rgb(252, 3, 223)
rgb (132, 101, 173)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
RGB(171, 29, 196)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (132, 101, 173)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
rgb (132, 101, 173)
rgb(181, 112, 164)
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
#cc529a
#c59445
rgb(245, 111, 66)
#c8cc0c
#bf6be3
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
rgb(11, 160, 224)
#e8085a
rgb(66, 135, 245)
#97d1a0
rgb(101, 11, 212)
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(125, 127, 130)
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
#2c990a
rbg(16, 162, 230)
rgb(110, 57, 65)
#d7da81
#f5ce42
rgb(80,199,199)
rgb(217, 7, 192)
#575662
rgb (247, 7, 79)
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
#49cde9
rgb(214, 139, 202)
rgb (132, 101, 173)
rgb(10, 191, 137)
#c20fce
rgb(80,199,199)
#d95d39
#eb5834